Alnylam Pharmaceuticals Inc. [NASDAQ: ALNY] price surged by 3.33 percent to reach at $4.41. A sum of 1644577 shares traded at recent session while its average daily volume was at 812.36K shares. Alnylam Pharmaceuticals Inc. shares reached a high of $138.2599 and dropped to a low of $132.88 until finishing in the latest session at $136.67.
The one-year ALNY stock forecast points to a potential upside of 11.83. The average equity rating for ALNY stock is currently 2.00, trading closer to a bullish pattern in the stock market.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Guru’s Opinion on Alnylam Pharmaceuticals Inc. [ALNY]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ALNY shares is $155.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ALNY stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
RBC Capital Mkts have made an estimate for Alnylam Pharmaceuticals Inc. shares, keeping their opinion on the stock as Sector Perform, with their previous recommendation back on May 13, 2020. While these analysts kept the previous recommendation, JP Morgan raised their target price from $133 to $137. The new note on the price target was released on May 07, 2020, representing the official price target for Alnylam Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $160, while Evercore ISI analysts kept a Outperform rating on ALNY stock.
The Average True Range (ATR) for Alnylam Pharmaceuticals Inc. is set at 6.28, with the Price to Sales ratio for ALNY stock in the period of the last 12 months amounting to 55.12. The Price to Book ratio for the last quarter was 11.42, with the Price to Cash per share for the same quarter was set at 11.64.
ALNY Stock Performance Analysis:
Alnylam Pharmaceuticals Inc. [ALNY] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.37. With this latest performance, ALNY shares dropped by -5.66% in over the last four-week period, additionally plugging by 13.78% over the last 6 months – not to mention a rise of 87.17% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ALNY stock in for the last two-week period is set at 52.51, with the RSI for the last a single of trading hit 59.23, and the three-weeks RSI is set at 53.79 for Alnylam Pharmaceuticals Inc. [ALNY]. The present Moving Average for the last 50 days of trading for this stock 134.25, while it was recorded at 129.72 for the last single week of trading, and 111.73 for the last 200 days.
Insight into Alnylam Pharmaceuticals Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Alnylam Pharmaceuticals Inc. [ALNY] shares currently have an operating margin of -427.50 and a Gross Margin at +88.60. Alnylam Pharmaceuticals Inc.’s Net Margin is presently recorded at -403.24.
Return on Total Capital for ALNY is now -61.11, given the latest momentum, and Return on Invested Capital for the company is -58.17. Return on Equity for this stock declined to -64.66, with Return on Assets sitting at -44.64. When it comes to the capital structure of this company, Alnylam Pharmaceuticals Inc. [ALNY] has a Total Debt to Total Equity ratio set at 21.12. Additionally, ALNY Total Debt to Total Capital is recorded at 17.44, with Total Debt to Total Assets ending up at 12.69. Long-Term Debt to Equity for the company is recorded at 19.19, with the Long-Term Debt to Total Capital now at 15.85.
Reflecting on the efficiency of the workforce at the company, Alnylam Pharmaceuticals Inc. [ALNY] managed to generate an average of -$669,778 per employee. Receivables Turnover for the company is 7.11 with a Total Asset Turnover recorded at a value of 0.11.Alnylam Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.50 and a Current Ratio set at 4.70.
ALNY Stock EPS
With the latest financial reports released by the company, Alnylam Pharmaceuticals Inc. posted -2.02/share EPS, while the average EPS was predicted by analysts to be reported at -1.86/share.When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -8.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ALNY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Alnylam Pharmaceuticals Inc. go to 46.09%.
Alnylam Pharmaceuticals Inc. [ALNY] Insider Position Details
There are presently around $14,328 million, or 95.80% of ALNY stock, in the hands of institutional investors. The top three institutional holders of ALNY stocks are: FMR LLC with ownership of 16,805,309, which is approximately 0.508% of the company’s market cap and around 0.50% of the total institutional ownership; WELLINGTON MANAGEMENT GROUP LLP, holding 12,286,778 shares of the stock with an approximate value of $1.63 billion in ALNY stocks shares; and VANGUARD GROUP INC, currently with $1.39 billion in ALNY stock with ownership of nearly 2.511% of the company’s market capitalization.
Positions in Alnylam Pharmaceuticals Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 176 institutional holders increased their position in Alnylam Pharmaceuticals Inc. [NASDAQ:ALNY] by around 8,028,551 shares. Additionally, 128 investors decreased positions by around 5,575,596 shares, while 64 investors held positions by with 94,729,693 shares. The mentioned changes placed institutional holdings at 108,333,840 shares, according to the latest SEC report filing. ALNY stock had 54 new institutional investments in for a total of 822,999 shares, while 34 institutional investors sold positions of 506,437 shares during the same period.